John Sharp
2017
In 2017, John Sharp earned a total compensation of $368.1K as Chief Financial Officer at PhaseBio Pharmaceuticals.
Compensation breakdown
| Non-Equity Incentive Plan | $50,985 |
|---|---|
| Option Awards | $8,950 |
| Salary | $307,500 |
| Other | $711 |
| Total | $368,146 |
Sharp received $307.5K in salary, accounting for 84% of the total pay in 2017.
Sharp also received $51K in non-equity incentive plan, $9K in option awards and $711 in other compensation.
Rankings
In 2017, John Sharp's compensation ranked 12,810th out of 14,666 executives tracked by ExecPay. In other words, Sharp earned more than 12.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 12,810 out of 14,666 | 13th |
Division Manufacturing | 5,034 out of 5,772 | 13th |
Major group Chemicals And Allied Products | 1,846 out of 2,075 | 11th |
Industry group Drugs | 1,537 out of 1,731 | 11th |
Industry Pharmaceutical Preparations | 1,191 out of 1,333 | 11th |
Source: SEC filing on April 5, 2019.
Sharp's colleagues
We found two more compensation records of executives who worked with John Sharp at PhaseBio Pharmaceuticals in 2017.